Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2016, Article ID 2605302, 3 pages
Case Report

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome

1Department of Medicine, University of Illinois College of Medicine, Chicago, IL, USA
2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA
3Division of Gastroenterology and Hepatology, University of Tennessee Health Sciences Center, Memphis, TN, USA

Received 31 July 2016; Accepted 11 October 2016

Academic Editor: Paola Di Carlo

Copyright © 2016 Eric R. Yoo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past, interferon-based therapy for chronic hepatitis C infection in patients with Down syndrome was noted to have lower efficacy and potentially higher risk of adverse effects. Recently, the treatment for chronic hepatitis C has been revolutionized with the introduction of interferon-free direct acting antivirals with favorable safety, tolerability, and efficacy profile. Based on our experiences, the newly approved sofosbuvir-based direct acting antiviral therapy is well tolerated and highly efficacious in this subpopulation of hepatitis C virus infected patients with Down syndrome.